Healio
Healio

Melanoma Video Perspectives

In a video interview, Vernon K. Sondak, MD, of Moffitt Cancer Center, discussed exciting treatment developments, cellular therapy, unmet needs in melanoma and more.

Choose a Section
  • Vernon K. Sondak, MD

    • Vernon K. Sondak, MD

    In a video interview, Vernon K. Sondak, MD, chair of the department of cutaneous oncology at Moffitt Cancer Center, discussed:

    • New roles of neoadjuvant therapy pre- and post-surgery;
    • Upcoming additional checkpoint inhibitors, stimulators in phase II and III clinical trials;
    • The "quiet revolution" in melanoma adaptive cellular therapy with tumor-infiltrating lymphocytes (TIL) and other immune therapies;
    • Effective, durable immune responses seen in a ‘cocktail’ of therapies, including IL-2, myelosuppressive preoperative chemotherapy;
    • The critical importance of identifying truly resistant patients and use of the TIL approach; and
    • A need to "tease out mechanisms of resistance" to provide appropriate treatments in patients.

    Read more about

    melanoma
    tumor infiltrating lymphocytes
    cell therapy